Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1998 Nov;15(10):599-604.
doi: 10.1023/a:1020381310860.

Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues

Affiliations
Comparative Study

Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues

M M Biljan et al. J Assist Reprod Genet. 1998 Nov.

Abstract

Purpose: Our purpose was to assess the effect of pretreatment with oral contraceptives (OCs) on the formation of functional ovarian cysts during pituitary suppression with gonadotropin-releasing hormone (GnRH) agonists, subsequent follicular development, and pregnancy rates.

Methods: A retrospective case-controlled study of 31 in vitro fertilization (IVF) patients, all of whom in a previous cycle had commenced the long protocol of GnRH-agonist (Buserelin) in the early follicular phase and were pretreated in a subsequent cycle with 2 weeks of an OC containing 30 micrograms of ethinyl estradiol and 150 micrograms of desogestrel prior to GnRH-agonist administration, was undertaken. Follow-up visits were arranged after a minimum of 11 days of GnRH-agonist administration and weekly thereafter until pituitary suppression was achieved.

Results: Cysts were detected in 16 (51.6%) of the 31 patients not pretreated with OCs, and in 0 (0%) of the 31 patients pretreated with OCs (odds ratio = 67.1; 95% confidence interval = 5.6-350.7). Patients pretreated with OCs achieved pituitary suppression more rapidly (median difference = 4 days; 95% confidence interval = 2-7) and had comparable gonadotropin requirements and pregnancy rates.

Conclusions: Pretreatment with OCs prior to pituitary suppression in the early follicular phase decreases ovarian cyst formation, without an apparent effect on subsequent follicular recruitment or pregnancy rates.

PIP: A retrospective case-controlled study was undertaken to assess the effects of pretreatment with oral contraceptive (OC) on the formation of functional ovarian cysts during pituitary suppression with gonadotropin-releasing hormone (GnRH) agonists, subsequently follicular development, and pregnancy rates. In the period between January 1997 and December 1997, 31 in vitro fertilizations, all of which in a previous cycle, had commenced the long protocol of GnRH agonists in the early follicular phase and were pretreated in a subsequent cycle with an OC containing 30 mcg ethinyl estradiol and 150 mcg desogestrel for 2 weeks prior GnRH agonist administration and then weekly until pituitary suppression was achieved. After data collection and analysis, findings revealed that functional ovarian cysts were detected in 16 (51.6%) of 31 patients not pretreated with an OC and in 0 (0%) of 31 patients pretreated with an OC. Satisfactory pituitary suppression was achieved more rapidly with patients pretreated with an OC. Further, comparable gonadotroph requirements and pregnancy rates were detected among patients pretreated with an OC. In conclusion, pretreating patients with an OC prior to pituitary suppression in the early follicular phase decreases ovarian cyst formation, without an apparent effect on subsequent follicular recruitment or pregnancy rates.

PubMed Disclaimer

References

    1. Tan SL, Maconochie N, Doyle P, Campbell S, Balen A, Bekir J, Brinsden P, Edwards RG, Jacobs HS. Cumulative conception and live-birth rates after in vitro fertilization with and without the use of long, short, and ultrashort regimens of the gonadotropin-releasing hormone agonist buserelin. Am J Obstet Gynecol. 1994;171:513–520. - PubMed
    1. Tan SL, Balen A, el Hussein E, Mills C, Campbell S, Yovich J, Jacobs HS. A prospective randomized study of the optimum timing of human chorionic gonadotropin administration after pituitary desensitization in in vitro fertilization. Fertil Steril. 1992;57:1259–1264. - PubMed
    1. Meldrum DR, Gutlay AL, Wisot A, Huynh D, Hamilton F, Kempton W. Timing of initiation and dose schedule of leuprolide influence the time course of ovarian suppresson. Fertil Steril. 1988;50:400–402. - PubMed
    1. Forman RG, Demouzon J, Feinstein MC, Testart J, Frydman R. Studies on the influence of gonadotrophin levels in the early follicular phase on the ovarian response to stimulation. Hum Reprod. 1991;6:113–117. - PubMed
    1. Shaker AG, Pittrof R, Zaidi J, Bekir J, Kyei-Mensah A, Tan SL. Administration of progestogens to hasten pituitary desensitization after the use of gonadotropin-releasing hormone agonist in in vitro fertilization—A prospective randomized study. Fertil Steril. 1995;64:791–795. - PubMed

Publication types

MeSH terms